全文获取类型
收费全文 | 9379篇 |
免费 | 454篇 |
国内免费 | 86篇 |
专业分类
耳鼻咽喉 | 117篇 |
儿科学 | 208篇 |
妇产科学 | 172篇 |
基础医学 | 1234篇 |
口腔科学 | 225篇 |
临床医学 | 551篇 |
内科学 | 2470篇 |
皮肤病学 | 306篇 |
神经病学 | 837篇 |
特种医学 | 345篇 |
外科学 | 1330篇 |
综合类 | 21篇 |
一般理论 | 1篇 |
预防医学 | 520篇 |
眼科学 | 123篇 |
药学 | 463篇 |
中国医学 | 8篇 |
肿瘤学 | 988篇 |
出版年
2023年 | 41篇 |
2022年 | 111篇 |
2021年 | 182篇 |
2020年 | 93篇 |
2019年 | 130篇 |
2018年 | 165篇 |
2017年 | 160篇 |
2016年 | 177篇 |
2015年 | 193篇 |
2014年 | 247篇 |
2013年 | 319篇 |
2012年 | 558篇 |
2011年 | 594篇 |
2010年 | 343篇 |
2009年 | 336篇 |
2008年 | 517篇 |
2007年 | 615篇 |
2006年 | 608篇 |
2005年 | 586篇 |
2004年 | 620篇 |
2003年 | 619篇 |
2002年 | 610篇 |
2001年 | 158篇 |
2000年 | 143篇 |
1999年 | 150篇 |
1998年 | 146篇 |
1997年 | 123篇 |
1996年 | 121篇 |
1995年 | 118篇 |
1994年 | 94篇 |
1993年 | 81篇 |
1992年 | 89篇 |
1991年 | 84篇 |
1990年 | 72篇 |
1989年 | 87篇 |
1988年 | 75篇 |
1987年 | 55篇 |
1986年 | 50篇 |
1985年 | 54篇 |
1984年 | 47篇 |
1983年 | 48篇 |
1982年 | 38篇 |
1981年 | 28篇 |
1980年 | 34篇 |
1979年 | 38篇 |
1978年 | 22篇 |
1977年 | 18篇 |
1976年 | 14篇 |
1975年 | 11篇 |
1972年 | 12篇 |
排序方式: 共有9919条查询结果,搜索用时 15 毫秒
991.
Spontaneous improvement of hematologic abnormalities in patients having juvenile myelomonocytic leukemia with specific RAS mutations
下载免费PDF全文
![点击此处可从《Blood》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Matsuda K Shimada A Yoshida N Ogawa A Watanabe A Yajima S Iizuka S Koike K Yanai F Kawasaki K Yanagimachi M Kikuchi A Ohtsuka Y Hidaka E Yamauchi K Tanaka M Yanagisawa R Nakazawa Y Shiohara M Manabe A Kojima S Koike K 《Blood》2007,109(12):5477-5480
Of 11 children with juvenile myelomonocytic leukemia (JMML) carrying RAS mutations (8 with NRAS mutations, 3 with KRAS2 mutations), 5 had a profound elevation in either or both the white blood cells and spleen size at diagnosis. Three patients had no or modest hepatosplenomegaly and mild leukocytosis at presentation but subsequently showed a marked increase in spleen size with or without hematologic exacerbation, for which nonintensive chemotherapy was initiated. The other three patients with NRAS or KRAS2 glycine to serine substitution received no chemotherapy, but hematologic improvement has been observed during a 2- to 4-year follow up. In the third group, all hematopoietic cell lineages analyzed had the RAS mutations at the time of hematologic improvement, whereas DNA obtained from the nails had the wild type. Additionally, numbers of circulating granulocyte-macrophage progenitors were significantly reduced during the clinical course. Thus, some patients with JMML with specific RAS mutations may have spontaneously improving disease. 相似文献
992.
Tahara T Arisawa T Wang F Shibata T Nakamura M Sakata M Hirata I Nakano H 《Cancer science》2007,98(11):1790-1794
Toll like receptors (TLR) play important roles in the signaling of many pathogen-related molecules and endogenous proteins associated with immune activation. The –196 to –174del polymorphism affects the TLR2 gene and alters its promoter activity. We investigated the influence of the TLR2 –196 to –174del polymorphism on the occurrence of non-cardiac gastric cancer (NCGC) in a Japanese population. The study was carried out with 289 patients with NCGC, 309 non-cancer patients with abdominal discomfort and 146 healthy controls. The –196 to –174del TLR2 polymorphism was investigated using the allele-specific polymerase chain reaction method in all of the subjects. The –196 to –174del/del genotype of TLR2 showed a significantly higher frequency in NCGC patients than in healthy controls (adjusted odds ratio [OR] = 6.06; 95% confidence interval [CI] = 1.86–19.72). Similarly, the frequency of the –196 to –174del/del genotype was significantly higher among NCGC patients than in non-cancer patients (adjusted OR = 2.02; 95% CI = 1.22–3.34). The same genotype was associated with an increased risk of both intestinal (OR = 2.00, 95% CI = 1.12–3.60) and diffuse-type (OR = 2.05; 95% CI = 1.11–3.79) histopathology. There were no significant associations between TLR2 genotypes and tumor stage and anatomical location. Our data suggest that the –196 to –174del/del genotype of TLR2 may increase the risk of gastric cancer in the Japanese population. ( Cancer Sci 2007; 98: 1790–1794) 相似文献
993.
Akhter M Kuriyama S Nakaya N Shimazu T Ohmori K Nishino Y Tsubono Y Fukao A Tsuji I 《European journal of cancer (Oxford, England : 1990)》2007,43(2):383-390
The association between alcohol consumption and the risk of cancer of the proximal or distal colon or rectum remains controversial. We examined this association in a large population-based cohort of Japanese men. In 1990, a self-administered questionnaire on alcohol drinking and other health habits was delivered to 25,279 Japanese men aged 40 to 64 years of age. After exclusion of subjects who gave incomplete responses on alcohol drinking or prevalent cancer cases at the baseline, a total of 21,199 men remained. Of these, 307 men were diagnosed as having colorectal cancer after 11 years of follow-up. Cox proportional hazards regression models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs), with adjustments made for potential confounders. Compared with never drinkers, past and current drinkers had multivariate HRs of 1.1 (95% CI, 0.6-1.9) and 1.6 (95% CI, 1.1-2.2) for colorectal cancer, respectively. A dose-response relationship with current volume of alcohol drinkers was observed for cancer of the distal colon and rectum, but not for proximal colon. The multivariate HRs for distal colon and rectal cancer among current heavy drinkers (45.6 g or more ethanol per day) as compared with never drinkers were 4.2 (1.6-10.7; p for trend=0.0002) and 1.8 (1.1-3.2; p for trend=0.04), respectively. In contrast, no significant linear association was found for proximal colon cancer (p for trend=0.2). These data indicate that alcohol consumption in Japanese men is associated with a statistically significant increased risk of cancer of the distal colon and rectum, but not cancer of the proximal colon. 相似文献
994.
Kijima T Suzuki M Ueda K Minami S Takeda Y Goya S Matsuoka H Kumagai T Yoshida M Osaki T Tachibana I Yokota S Kawase I 《Oncology research》2007,16(10):489-495
The tyrosine kinase inhibitor (TKI) of the epidermal growth factor receptor (EGFR) gefitinib has beneficial effect in some patients with refractory advanced non-small cell lung cancer (NSCLC). However, the majority of responders eventually develop acquired resistance during the course of prolonged continuous treatment. Here we present a case of 76-year-old Japanese female, who had never smoked, with poor performance status from bronchioloalveolar carcinoma (BAC), in whom a brief initial 5-week administration of gefitinib resulted in dramatic antitumor effects that lasted approximately 8.5 months after cessation of the treatment. Furthermore, the relapsed tumor later regressed again by re-treatment with the TKI. She survived 26 months since she first took gefitinib. Unexpectedly, neither sensitizing mutations for EGFR-TKIs nor increased copy numbers were detected in EGFR gene of her BAC cells. This case suggests that, in some patients with NSCLC, even short-term administration of gefitinib may bring about clinical benefits and disease response comparable to the standard long-term daily dosing schedule. Short-term use of gefitinib will also be able to minimize the expensive medical cost of the TKI. The potential role of short-term or pulse-dose therapy with EGFR-TKIs should be clarified in further prospective studies. Moreover, it is urgent to develop better strategies by which we could distinguish responders to the TKIs from nonresponders among patients who do not have any EGFR gene alterations. 相似文献
995.
Relationship between the loss of heterozygosity and tobacco smoking in pulmonary adenocarcinoma 总被引:2,自引:0,他引:2
Yohena T Yoshino I Takenaka T Ohba T Kouso H Osoegawa A Hamatake M Oda S Kuniyoshi Y Maehara Y 《Oncology research》2007,16(7):333-339
A loss of heterozygosity (LOH) is a major cause of lung carcinogenesis, and it is considered to be related to tobacco smoking in central type lung cancer. We investigated the relationship between LOH in lung adenocarcinoma and tobacco smoking. In a consecutive series of 50 patients with lung adenocarcinoma who underwent a surgical resection, cancer tissue specimens and corresponding normal peripheral lung and central bronchial tissue specimens were analyzed for LOH at the regions of D3S1234 (FHIT), D3S1300 (FHIT), D9S171 (CDKN2), and D17S796 (p53) by polymerase chain reaction using four fluorescence-labeled dinucleotide markers. To examine how cells are influenced by smoking, the A549 cell line was exposed to benzo[a]pyrene (B[a]P) for 24 weeks and then was subjected to the above analysis. The LOH in cancer tissue was thus detected in four (17%) patients at D3S1234, six (14%) at D3S1300, and seven (18%) at D17S796, but no LOH was detected in any normal tissue specimens. The incidence of LOHs in cancer tissue specimens from active smokers was 21% at D3S1234, 11% at D3S1300, and 19% at D17S796, whereas that of LOHs from nonactive smokers was 0% at D3S1234, 19% at D3S1300, and 14% at D17S796. Analyzing the relationship between the pack-year index and the presence of LOH, a significant difference was found among the active smokers. Besides, in the A549 cell line exposed to B[a]P, LOH was de novo detected in one (D2S123) of the nine regions examined. The incidence of LOH could be influenced by tobacco smoking in lung adenocarcinoma, thus suggesting the presence of an important event in the carcinogenesis of this disease. 相似文献
996.
997.
Suyama K Noguchi Y Tanaka T Yoshida T Shibata T Saito Y Tatsuno I 《Oncology reports》2007,18(5):1291-1298
Bisphosphonates cause apoptosis to various types of cancer cells including breast cancer. Inhibition of the mevalonate pathway was reported to be involved in the apoptosis induced by bisphosphonates, but its precise mechanism has not been unveiled. In the present study, we investigated the molecular mechanism of risedronate, a bisphosphonate, in the apoptosis of the breast cancer cell line MCF-7 in comparison with that of cerivastatin, an HMG CoA reductase inhibitor (statin), since statin has been known to induce apoptosis through an isoprenoid-dependent pathway in these cells. We found that i) risedronate induced MCF-7 cells into apoptosis in a manner similar to cerivastatin with the activation of caspase-9 followed by caspase-6 and -7, that ii) bisphosphonate-induced apoptosis was significantly, but not fully, recovered by the addition of GGOH, an isoprenoid, which completely rescued in case of cerivastatin-induced apoptosis, that iii) risedronate induced G2 arrest with the induction of Bim (BH3-only protein), but that statin induced G1 arrest without it, and that iv) the down-regulation of Bim protein by siRNA significantly attenuated the risedronate-induced apoptosis. These data clearly indicate that both isoprenoid-dependent and -independent pathways might be involved in the apoptosis induced by bisphosphonate, and Bim might be a critical component for the isoprenoid-independent apoptotic pathway. 相似文献
998.
999.
Quetiapine has been suggested to be useful for the treatment of psychosis in patients with Parkinson's disease without prominent deterioration of motor functions. We present two patients with Parkinson's disease in whom administration of quetiapine for drug-induced psychosis caused characteristic stereotyped behaviors or punding. Since stereotyped behaviors are usually associated with excessive dopaminergic activity, it is clinically important to note that stereotyped behaviors or punding may be induced by an atypical antipsychotic drug for the treatment of psychosis in patients with Parkinson's disease. 相似文献
1000.